Terms: = Head and neck cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
248 results:
1. New treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung cancer Focusing on
Saw SPL; Le X; Hendriks LEL; Remon J
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
[TBL] [Abstract] [Full Text] [Related]
2. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory alk-positive NSCLC from a phase II study.
Zheng J; Wang T; Yang Y; Huang J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wang H; Cang S; Wu N; Song W; Liu X; Zhao S; Ding L; Selvaggi G; Wang Y; Xiao S; Wang Q; Shen Z; Zhou J; Zhou J; Zhang L
Cancer Commun (Lond); 2024 Apr; 44(4):455-468. PubMed ID: 38421881
[TBL] [Abstract] [Full Text] [Related]
3. Induction chemotherapy followed by response evaluation and esophagectomy for advanced esophageal cancer.
van der Zijden CJ; van der Sluis PC; Mostert B; Nuyttens JJME; Spaander MCW; Toxopeus ELA; Valkema R; Beerepoot LV; van Halteren HK; Lagarde SM; Wijnhoven BPL
Eur J Surg Oncol; 2024 Mar; 50(3):107968. PubMed ID: 38241878
[TBL] [Abstract] [Full Text] [Related]
4. Value of blood oxygenation level-dependent magnetic resonance imaging in early evaluation of the response and prognosis of esophageal squamous cell carcinoma treated with definitive chemoradiotherapy: a preliminary study.
Zheng H; Zhang H; Zhu Y; Wei X; Liu S; Ren W
BMC Med Imaging; 2024 Jan; 24(1):18. PubMed ID: 38216885
[TBL] [Abstract] [Full Text] [Related]
5. Mapping the impact of malnutrition as defined by the Global Leadership Initiative on Malnutrition and nutrition impact symptoms on the possibility of returning to work after treatment for head and neck cancer.
Einarsson S; Bokström A; Laurell G; Tiblom Ehrsson Y
Support Care Cancer; 2023 Dec; 32(1):55. PubMed ID: 38133825
[TBL] [Abstract] [Full Text] [Related]
6. Patterns of treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract] [Full Text] [Related]
7. High-grade intraductal carcinoma of the parotid gland harboring CTNNA1::alk rearrangement: Changes in genetic status using genetic testing during treatment with an alk inhibitor.
Watanabe T; Honma Y; Yonemori K; Sunami K; Yoshimoto S; Mori T
Head Neck; 2024 Mar; 46(3):E26-E31. PubMed ID: 38018800
[TBL] [Abstract] [Full Text] [Related]
8. cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in alk-rearrangement positive non-small cell lung cancer (NSCLC).
Lee SY; Cho HJ; Choi J; Ku B; Moon SW; Moon MH; Kim KS; Hyun K; Kim TJ; Sung YE; Hwang Y; Lee E; Ahn DH; Choi JY; Lim JU; Park CK; Kim SW; Kim SJ; Koo IS; Jung WS; Lee SH; Yeo CD; Lee DW
J Exp Clin Cancer Res; 2023 Nov; 42(1):309. PubMed ID: 37993887
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of the Thyroid cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
[No Abstract] [Full Text] [Related]
10. Therapeutic inhibition of ATR in differentiated thyroid cancer.
Lin SF; Lee YY; Wu MH; Lu YL; Yeh CN; Chen WY; Chou TC; Wong RJ
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902083
[TBL] [Abstract] [Full Text] [Related]
11. Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial.
Hernando-Calvo A; Malone E; Day D; Prawira A; Weinreb I; Yang SYC; Wong H; Rodriguez A; Jennings S; Eliason A; Wang L; Spreafico A; Siu LL; Hansen AR
Cancer Med; 2023 Oct; 12(20):20299-20310. PubMed ID: 37818869
[TBL] [Abstract] [Full Text] [Related]
12. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
Wolf J; Souquet PJ; Goto K; Cortot A; Baik C; Heist R; Kim TM; Han JY; Neal JW; Mansfield AS; Gilloteau I; Nwana N; Waldron-Lynch M; Davis KL; Giovannini M; Awad MM
Clin Lung Cancer; 2023 Nov; 24(7):641-650.e2. PubMed ID: 37741716
[TBL] [Abstract] [Full Text] [Related]
13. Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology.
Wang Y; Song W; Li Y; Liu Z; Zhao K; Jia L; Wang X; Jiang R; Tian Y; He X
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16837-16850. PubMed ID: 37733241
[TBL] [Abstract] [Full Text] [Related]
14. Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
Lee JM; McNamee CJ; Toloza E; Negrao MV; Lin J; Shum E; Cummings AL; Kris MG; Sepesi B; Bara I; Kurtsikidze N; Schulze K; Ngiam C; Chaft JE
J Thorac Oncol; 2023 Nov; 18(11):1458-1477. PubMed ID: 37451404
[TBL] [Abstract] [Full Text] [Related]
15. Nanotechnological Advancements for the Theranostic Intervention in Anaplastic Thyroid cancer: Current Perspectives and Future Direction.
Uppalapati SS; Guha L; Kumar H; Mandoli A
Curr Cancer Drug Targets; 2024; 24(3):245-270. PubMed ID: 37424349
[TBL] [Abstract] [Full Text] [Related]
16. Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal cancer: A Systematic Review and Meta-analysis.
Su F; Yang X; Yin J; Shen Y; Tan L
Ann Surg Oncol; 2023 Nov; 30(12):7461-7471. PubMed ID: 37400616
[TBL] [Abstract] [Full Text] [Related]
17. Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years.
Silver A; Ho C; Ye Q; Zhang J; Janzen I; Li J; Martin M; Wu L; Wang Y; Lam S; MacAulay C; Melosky B; Yuan R
Curr Oncol; 2023 Jun; 30(6):5546-5559. PubMed ID: 37366902
[TBL] [Abstract] [Full Text] [Related]
18. Influence factors and nomogram for volume reduction rate in benign thyroid nodule after thermal ablation.
Cao S; Wang L; Wei Y; Zhao Z; Wu J; Yu M
Int J Hyperthermia; 2023; 40(1):2220562. PubMed ID: 37344375
[TBL] [Abstract] [Full Text] [Related]
19. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
Saad MB; Hong L; Aminu M; Vokes NI; Chen P; Salehjahromi M; Qin K; Sujit SJ; Lu X; Young E; Al-Tashi Q; Qureshi R; Wu CC; Carter BW; Lin SH; Lee PP; Gandhi S; Chang JY; Li R; Gensheimer MF; Wakelee HA; Neal JW; Lee HS; Cheng C; Velcheti V; Lou Y; Petranovic M; Rinsurongkawong W; Le X; Rinsurongkawong V; Spelman A; Elamin YY; Negrao MV; Skoulidis F; Gay CM; Cascone T; Antonoff MB; Sepesi B; Lewis J; Wistuba II; Hazle JD; Chung C; Jaffray D; Gibbons DL; Vaporciyan A; Lee JJ; Heymach JV; Zhang J; Wu J
Lancet Digit Health; 2023 Jul; 5(7):e404-e420. PubMed ID: 37268451
[TBL] [Abstract] [Full Text] [Related]
20. Inflammatory myofibroblastic tumor of the thyroid gland.
Zhang Y; Liu J
Front Endocrinol (Lausanne); 2023; 14():1156117. PubMed ID: 37255972
[TBL] [Abstract] [Full Text] [Related]
[Next]
